Physician profile
Kevin Freeman
NPI 1427069806
$5,154.81
in general payments reported to CMS, 2019-2025
17 companies · $658 in 2025
The $658 reported for 2025 was more than what 83% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,637 · 2020: $290 · 2021: $535 · 2022: $734 · 2023: $903 · 2024: $398 · 2025: $658.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,941 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,940.57 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $1,189.61 | 2019-2025 | Tecnis Iol, Tecnis Iol |
| Alcon Vision LLC | $866.69 | 2019-2025 | Clareon, Rocklatan, Eysuvis |
| Sun Pharmaceutical Industries INC. | $572.23 | 2020-2025 | Cequa |
| Allergan, INC. | $360.44 | 2019-2021 | |
| Harrow Eye, LLC | $331.75 | 2024-2025 | Vevye |
| Dompe US, INC. | $328.44 | 2022-2025 | Oxervate |
| Aerie Pharmaceuticals, INC. | $327.12 | 2019-2021 | |
| Oyster Point Pharma, INC. | $313.03 | 2022-2025 | Tyrvaya, Ryzumvi |
| Abbvie INC. | $242.40 | 2022-2025 | |
| Glaukos Corporation | $160.72 | 2019-2023 | |
| Rxsight INC | $124.95 | 2022 | |
| Novartis Pharmaceuticals Corporation | $96.85 | 2019-2023 | |
| Ivantis, INC | $84.09 | 2019 | |
| Bausch & Lomb Americas INC. | $80.25 | 2023-2025 | Miebo, Vyzulta |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $43.66 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $20.07 | 2019 | |
| Sight Sciences, INC. | $12.51 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Freeman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.